• Publications
  • Influence
Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients
BackgroundPrader-Willi syndrome (PWS) is a complex neurodevelopmental genetic disorder with hypothalamic dysfunction, early morbid obesity with hyperphagia, and specific psychiatric phenotypesExpand
  • 70
  • 4
A neuropsychological assessment of frontal cognitive functions in Prader-Willi syndrome.
BACKGROUND Prader-Willi syndrome (PWS) is associated with a characteristic behavioural phenotype whose main features are, alongside compulsive hyperphagia, deficits in social behaviour: socialExpand
  • 67
  • 4
Cognitive profile in a large French cohort of adults with Prader-Willi syndrome: differences between genotypes.
BACKGROUND Prader-Willi syndrome (PWS) is a rare genetic disorder characterised by developmental abnormalities leading to somatic and psychological symptoms. These include dysmorphic features,Expand
  • 49
  • 4
Growth hormone therapy for children and adolescents with Prader-Willi syndrome is associated with improved body composition and metabolic status in adulthood.
CONTEXT Children with Prader-Willi syndrome (PWS) who receive GH treatment have improved growth and body composition; however, data are lacking for adults when treatment is discontinued afterExpand
  • 41
  • 1
Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature
AbstractPrader-Willi syndrome (PWS) is a rare genetic syndrome. The phenotype includes moderate to intellectual disability, dysmorphia, obesity, and behavioral disturbances (e.g., hetero andExpand
  • 25
  • PDF
Medical, psychological and social features in a large cohort of adults with Prader-Willi syndrome: experience from a dedicated centre in France.
BACKGROUND Prader-Willi syndrome (PWS) is a developmental genetic disorder characterised by a variable expression of medical, cognitive and behavioural symptoms. In adulthood, the prevalence andExpand
  • 31
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
Context and objective Prader-Willi syndrome (PWS) is characterized by early-onset hyperphagia and increased circulating levels of the orexigenic Acylated Ghrelin (AG) hormone with a relative deficitExpand
  • 26
Behavioral profile of adults with Prader-Willi syndrome: correlations with individual and environmental variables
BackgroundMaladaptive behavior has been reported as a phenotypical feature in Prader–Willi syndrome (PWS). It severely limits social adaptation and the quality of life of children and adults with theExpand
  • 21
Assessment of executive functions in Prader-Willi syndrome and relationship with intellectual level.
INTRODUCTION The aim of the present study was to determine whether individuals with Prader-Willi syndrome (PWS) have impaired global executive functioning and whether this deficit is linked withExpand
  • 12
Causes of death in Prader-Willi syndrome: lessons from 11 years’ experience of a national reference center
BackgroundIn the last 20 years, substantial improvements have been made in the diagnosis, treatment and management of patients with Prader-Willi syndrome (PWS). Few data on causes of death areExpand
  • 8